Pet King Brands' ZYMOX® Designated as a 2025 Vanguard Awards Winner in Eye and Ear Care
AUSTIN, Texas, June 30, 2025 /PRNewswire/ — Pet King Brands, a pioneering leader in veterinarian-recommended enzymatic pet health products, including ZYMOX Dermatology and Oratene® Brushless Oral Care, is honored to announce their recognition as a Pet Insight Magazine 2025 Vanguard Award recipient.
The annual awards program certifies category giants through their leadership, innovation and partnership, 'pushing forward trustworthy solutions in their categories, backing up their innovations with more research than ever,' says Pet Insight.
Pet King Brands leads the eye and ear care category with an emphasis on safe, effective and natural solutions in accessible and convenient formats.
'We use only natural, enzyme-based formulas to provide therapeutic relief from common pet ailments,' said Debra Decker, Director of Marketing of Pet King Brands, in an interview with Pet Insight. 'Our LP3 Enzyme System sets us apart by targeting the root causes of infections, reducing the frequency of chronic issues and providing lasting relief all while offering preventative protection for long-term health. The enzymes in ZYMOX products are derived from natural dairy sources, ensuring that pets receive a chemical-free, gentle experience without harmful side effects.'
Learn more about this year's Pet Insight 'Vanguard Awards' and see a complete list of winners here.
About Pet King BrandsPet King Brands, proud sponsors of The Westminster Kennel Club's 149th Dog Show and makers of ZYMOX® Ear and Skin, Oratene® Brushless Oral Care, Equine Defense®, and ZYLAFEN™ products, is a leader in veterinarian-approved pet products made in the USA. Focused on the health and wellness of small and large animals of all ages, the products utilize the power of the LP3 Enzyme System and have been resolving ear, skin and oral conditions for over 25 years. Led by President and Founder Pamela Bosco, with the help of her bioscientist brother, Michael Pellico, Pet King Brands has revolutionized the way people care for animals' ears, skin and mouths, offering solutions that are gentle, easy to administer and free of harsh chemicals and antibiotics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. 'Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth,' said Dr. Helen Torley, President and CEO of Halozyme. 'The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future.' The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney
Malaysian Reserve
17 hours ago
- Malaysian Reserve
Pet King Brands' ZYMOX® Designated as a 2025 Vanguard Awards Winner in Eye and Ear Care
Pet Insight Magazine recognizes ZYMOX as a category trailblazer. AUSTIN, Texas, June 30, 2025 /PRNewswire/ — Pet King Brands, a pioneering leader in veterinarian-recommended enzymatic pet health products, including ZYMOX Dermatology and Oratene® Brushless Oral Care, is honored to announce their recognition as a Pet Insight Magazine 2025 Vanguard Award recipient. The annual awards program certifies category giants through their leadership, innovation and partnership, 'pushing forward trustworthy solutions in their categories, backing up their innovations with more research than ever,' says Pet Insight. Pet King Brands leads the eye and ear care category with an emphasis on safe, effective and natural solutions in accessible and convenient formats. 'We use only natural, enzyme-based formulas to provide therapeutic relief from common pet ailments,' said Debra Decker, Director of Marketing of Pet King Brands, in an interview with Pet Insight. 'Our LP3 Enzyme System sets us apart by targeting the root causes of infections, reducing the frequency of chronic issues and providing lasting relief all while offering preventative protection for long-term health. The enzymes in ZYMOX products are derived from natural dairy sources, ensuring that pets receive a chemical-free, gentle experience without harmful side effects.' Learn more about this year's Pet Insight 'Vanguard Awards' and see a complete list of winners here. About Pet King BrandsPet King Brands, proud sponsors of The Westminster Kennel Club's 149th Dog Show and makers of ZYMOX® Ear and Skin, Oratene® Brushless Oral Care, Equine Defense®, and ZYLAFEN™ products, is a leader in veterinarian-approved pet products made in the USA. Focused on the health and wellness of small and large animals of all ages, the products utilize the power of the LP3 Enzyme System and have been resolving ear, skin and oral conditions for over 25 years. Led by President and Founder Pamela Bosco, with the help of her bioscientist brother, Michael Pellico, Pet King Brands has revolutionized the way people care for animals' ears, skin and mouths, offering solutions that are gentle, easy to administer and free of harsh chemicals and antibiotics.
Malaysian Reserve
19 hours ago
- Malaysian Reserve
FMC Corporation expands novel fluindapyr fungicide technology to EMEA region
Tremisia® fungicide receives registration in Ukraine, bringing growers a new tool to combat challenging crop diseases PHILADELPHIA, June 30, 2025 /PRNewswire/ — FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced regulatory approval for Tremisia® fungicide in Ukraine, marking the first introduction of the company's novel fluindapyr technology in the European, Middle East, and Africa (EMEA) region. The approval covers oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland. 'The registration advances the commercialization of FMC's novel fluindapyr fungicide technology,' said Sebastià Pons, vice president, president of FMC EMEA. 'Ukraine ranks among the world's largest exporters of sunflower, oilseed rape, and wheat, making it a strategically important agricultural market. The Tremisia® fungicide approval brings Ukrainian growers our most advanced fungicide technology and demonstrates FMC's continued commitment to science and innovation.' Tremisia® fungicide combines FMC's proprietary fluindapyr molecule with flutriafol, delivering a dual mode of action to help maintain a healthy crop for an extended period. This fungicide targets a broad spectrum of economically significant diseases, including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat. 'This registration fills an important gap in disease management options for Ukrainian growers, providing a high-performance tool to protect their crops from devastating disease,' said Nataliia Savchenko, FMC Ukraine country leader. 'Disease pressures pose ongoing challenges to crop productivity in Ukraine's intensive cropping systems. Tremisia® fungicide will offer growers the freedom to choose a best-in-class solution that integrates seamlessly into their existing disease management programs.' The Ukraine registration builds on FMC's successful commercialization of fluindapyr-based products in Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States, with conditional approval secured in the Philippines earlier this year. Pending regulatory decisions, FMC anticipates launching fluindapyr-based products in Bolivia, Chile, Colombia, Honduras, and India, further expanding global access to this innovative fungicide technology. About FMC FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit to learn more and follow us on LinkedIn®. Tremisia is a trademark of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are 'forward-looking' and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders. In some cases, FMC has identified these forward-looking statements by such words or phrases as 'outlook', 'will likely result,' 'is confident that,' 'expect,' 'expects,' 'should,' 'could,' 'may,' 'will continue to,' 'believe,' 'believes,' 'anticipates,' 'predicts,' 'forecasts,' 'estimates,' 'projects,' 'potential,' 'intends' or similar expressions identifying 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 (the '2024 Form 10-K'), the section captioned 'Forward-Looking Information' in Part II of the 2024 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ('SEC'). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.
